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Abstract The presence of AbpE3 (N-terminal truncated
Ab starting with pyroglutamate) in Alzheimer’s disease
(AD) has received considerable attention since the dis-
covery that this peptide represents a dominant fraction of
Ab peptides in senile plaques of AD brains. This was later
conﬁrmed by other reports investigating AD and Down’s
syndrome postmortem brain tissue. Importantly, AbpE3 has
a higher aggregation propensity, and stability, and shows
an increased toxicity compared to full-length Ab. We have
recently shown that intraneuronal accumulation of AbpE3
peptides induces a severe neuron loss and an associated
neurological phenotype in the TBA2 mouse model for AD.
Given the increasing interest in AbpE3, we have generated
two novel monoclonal antibodies which were characterized
as highly speciﬁc for AbpE3 peptides and herein used to
analyze plaque deposition in APP/PS1KI mice, an AD
model with severe neuron loss and learning deﬁcits. This
was compared with the plaque pattern present in brain
tissue from sporadic and familial AD cases. Abundant
plaques positive for AbpE3 were present in patients with
sporadic AD and familial AD including those carrying
mutations in APP (arctic and Swedish) and PS1. Interest-
ingly, in APP/PS1KI mice we observed a continuous
increase in AbpE3 plaque load with increasing age, while
the density for Ab1-x plaques declined with aging. We
therefore assume that, in particular, the peptides starting
with position 1 of Ab are N-truncated as disease pro-
gresses, and that, AbpE3 positive plaques are resistant to
age-dependent degradation likely due to their high stability
and propensity to aggregate.
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Introduction
Alzheimer’s disease (AD) is a progressive neurodegener-
ative disorder characterized by the presence of extracellular
amyloid plaques composed of amyloid-b (Ab) surrounded
by dystrophic neurites and neuroﬁbrillary tangles. The
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may be caused by an enhanced production of Ab peptides
have led to the hypothesis that amyloidogenic Ab is inti-
mately involved in the AD pathogenic process (Selkoe
1998). Besides Ab peptides starting with an aspartate at
position 1, a variety of different N-truncated Ab peptides
have been identiﬁed in AD brains. Ragged peptides with a
major species including those beginning with phenylala-
nine at position 4 of Ab have been reported as early as
1985 by Masters et al. (1985a, b)). In contrast, no N-ter-
minal sequence could be obtained from cores puriﬁed in a
sodium dodecyl sulfate-containing buffer, which led to the
assumption that the N-terminus could be blocked (Gorevic
et al. 1986; Selkoe et al. 1986). The presence of AbpE3
(N-terminal truncated Ab starting with pyroglutamate) in
AD brain was subsequently shown using mass spectrome-
try of puriﬁed Ab peptides, explaining at least partially
initial difﬁculties in sequencing Ab peptides puriﬁed from
human brain tissue (Mori et al. 1992). The authors reported
that only 10–15% of the total Ab isolated by this method
begins at position 3 with AbpE3. Saido et al. (1995) then
showed that AbpE3 represents a dominant fraction of Ab
peptides in senile plaques of AD brains. This was later
conﬁrmed by other reports investigating AD and Down’s
syndrome postmortem brain tissue (Guntert et al. 2006;
Harigaya et al. 2000; Hosoda et al. 1998; Iwatsubo et al.
1996; Kuo et al. 1997, 2001; Miravalle et al. 2005; Piccini
et al. 2005, 2007; Russo et al. 1997; Saido et al. 1996,
Tekirian et al. 1998, Wegiel et al. 2007).
In general, N-terminal deletions in general enhance
aggregation of b-amyloid peptides in vitro (Pike et al.
1995; Masters et al. 1985a, b). Importantly, AbpE3 has a
higher aggregation propensity (He and Barrow 1999;
Schilling et al. 2006), and stability (Kuo et al. 1998), and
shows an increased toxicity compared to full-length Ab
(Russo et al. 2002). Ku et al. (2001) have used an inte-
grated chemical and morphological comparison of the Ab
peptides and amyloid plaques present in the brains of
APP23 transgenic mice and human AD patients. The lack
of post-translational modiﬁcations such as N-terminal
degradation, isomerization, racemization and pyroglutamyl
formation of Ab from APP23 mice provides an explanation
for the differences in solubility of Ab from human AD and
transgenic mouse plaques. This group also demonstrated
that in another transgenic mouse model (Tg2576), Ab
peptides lacked a pronounced N-terminal degradation,
post-translational modiﬁcations and cross-linkages that
were frequently observed in the compact Ab peptide
deposits found in AD brain. Thus, under in vivo conditions,
truncated Ab molecules appeared to be generated by
hydrolysis at multiple sites rather than by postmortem
N-terminal degradation (Kalback et al. 2002). Recently, it
has been demonstrated that the N-terminal pE-formation
can be catalyzed by glutaminyl cyclase (QC) which phar-
macologically is interfered by a QC inhibitor, both in vitro
(Cynis et al. 2008) and in vivo (Schilling et al. 2008). QC
expression was found up-regulated in the cortex of patients
with AD and correlated with the appearance of pE-modi-
ﬁed Ab. Oral application of a glutaminyl cyclase inhibitor
resulted in reduced AbpE3-42 burden in two different
transgenic mouse models of AD and in a new Drosophila
model. Interestingly, treatment of these mice was accom-
panied by reductions in Abx-40/42, diminished plaque for-
mation and gliosis, as well as improved performance in
context memory and spatial learning tests (Schilling et al.
2008).
A promising experimental approach to unravel the role
of Ab in AD pathology has been the generation of trans-
genic mice overexpressing the amyloid precursor protein
(APP). All mouse models mimic the typical AD-like
pathological deﬁcits in synaptic transmission (Hsia et al.
1999), changes in behavior, differential glutamate respon-
ses and deﬁcits in long-term potentiation. These charac-
teristics are generally attributed to the overexpression of
full-length APP (Moechars et al. 1999). Although learning
deﬁcits (Billings et al. 2005; Holcomb et al. 1998; Oakley
et al. 2006; Puolivali et al. 2002) were evident in various
APP models, the extent of Ab-amyloid deposition did not
correlate with the behavioral phenotype (Holcomb et al.
1999). In the past, extracellular Ab has been regarded as
the causative agent, whereas more recent evidence now
points to toxic effects of Ab in intracellular compartments
(Tseng et al. 2004; Wirths et al. 2004). In addition, another
concept proposes that the soluble oligomers and the b-sheet
containing amyloid ﬁbrils are the toxic forms of Ab
(Harmeier et al. 2009; Klein 2002; Selkoe 2001). It has
further been demonstrated that soluble oligomeric Ab42,
but not plaque-associated Ab, correlates best with cogni-
tive dysfunction in AD (McLean et al. 1999; Naslund et al.
2000). Oligomers are formed preferentially intracellularly
within neuronal processes and synapses rather than extra-
cellularly (Takahashi et al. 2004; Walsh et al. 2000). Pre-
viously, we have reported that intraneuronal Ab rather than
extracellular plaque pathology correlates with neuron loss
in the hippocampus (Casas et al. 2004), the frontal cortex
(Christensen et al. 2008b) and the cholinergic system
(Christensen et al. 2008a) of APP/PS1KI mice expressing
transgenic human mutant APP751 including the Swedish
and London mutations on a murine knock-in (KI) Prese-
nilin 1 (PS1) background with two FAD-linked mutations
(PS1M233T and PS1L235P). The APP/PS1KI mice exhibit
robust learning deﬁcits at the age of 6 months (Wirths et al.
2008), age-dependent axonopathy (Wirths et al. 2007),
neuron loss in hippocampus CA1 together with synaptic
deﬁcits, and hippocampus atrophy coinciding with intran-
euronal aggregation of N-terminal modiﬁed Ab variants
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123(Breyhan et al. 2009). Notably, the APP/PS1KI mouse
model exhibits a large heterogeneity of N-truncated Abx-42
variants (Casas et al. 2004). Recently, we generated a new
mouse model expressing only N-truncated AbpE3 in neu-
rons, and demonstrated for the ﬁrst time that this peptide is
neurotoxic in vivo inducing neuron loss and an associated
neurological phenotype (Wirths et al. 2009).
Given the increasing interest in AbpE3, we have gener-
ated two novel monoclonal antibodies which we have
characterized as highly speciﬁc for AbpE3 peptides and
herein used to analyze plaque deposition in APP/PS1KI
mice, an AD model with severe neuron loss and learning
deﬁcits, and compared this pattern with that present in
brain tissue from sporadic and familial AD cases.
Materials and methods
Antibodies
Two novel antibodies 1-57 and 2-48 against N-terminal
truncated Ab starting with pyroglutamate (pGlu, pE) were
generated by Synaptic Systems (Goettingen, Germany) by
immunizing three Balb/c mice with a KLH-coupled pyr-
oglutamate-Abeta-peptide with the peptide pEFRHD-C.
After preparation of the lymph nodes, cells were fused with
the myeloma cell line P3-963-Ag8. The hybridoma
supernatants of mixed clones were screened by ELISA and
subcloned. The monoclonal antibodies 1-57 (IgG2b) and
2-48 (IgG1) were selected and further characterized for
their speciﬁcity and afﬁnity (see below). Other monoclonal
anti-Ab antibodies used for comparison are 4G8 (Ab epitope
17-24; Covance), HJ5.1 (Ab 13-28, courtesy of Hong Jiang
and DavidHoltzman) andAb[N] (IBL, Hamburg,Germany).
Surface plasmon resonance analysis (BIAcore)
To obtain afﬁnity data, a BIAcore3000 system (GE
Healthcare, Uppsala, Sweden) with the BIAcontrol soft-
ware (Version 4.1) was used. Ab peptides (PSL, Heidel-
berg, Germany; Ab1-38,A b3-38,A bpE3-38) were solubilized
and monomerized in 50% formic acid, lyophilized, and re-
solubilized in 0.12% ammonia to obtain stock solutions of
1 lg/ll [see also (Harmeier et al. 2009)]. The Ab peptides
were then immobilized by amine coupling (Amine Cou-
pling Kit, GE Healthcare, Uppsala, Sweden) to CM5-chips
at pH 4.5 after preparing dilutions (ﬁnal peptide concen-
trations were 20 lg/ml) in coupling buffer (10 mM Na-
Acetate pH 4.5), as running buffer HBS-EP (10 mM
HEPES pH 7.4, 150 mM NaCl, 3 mM EDTA, 0,005%
P20) was used. The monoclonal antibodies 1-57 and 2-48
were diluted in running buffer and tested in a concentration
range from 1 to 35 lg/ml at ﬂow rates of 15 or 20 ll/min,
respectively. Injection times varied from 5 to 20 min. The
antibodies Ab[N] (IBL, Hamburg, Germany) and 4G8
(Covance, USA) were used at concentrations of 10 lg/ml.
The chip surface was regenerated after each antibody
injection by a 90 s pulse injection with buffer containing
8 M urea at a ﬂow rate of 100 ll/min. Binding curves were
evaluated with the BIA evaluation software (Version 4.1).
All chemicals were obtained from Roth (Karlsruhe,
Germany) except for HEPES (Sigma-Aldrich, Mu ¨nchen,
Germany) and P20 (GE Healthcare, Uppsala, Sweden).
Transgenic mice
The generation of APP/PS1KI mice has been described
previously (Casas et al. 2004). In brief, human mutant
APP751 containing the Swedish and London mutations is
overexpressed under the control of the murine Thy-1 pro-
moter, whereas murine PS1 with the M233T and L235P
FAD-linked mutations is expressed under the control of the
endogenous mouse PS1 promoter. APP/PS1KI mice were a
generousgiftofDr.LaurentPradier,Sanoﬁ-Aventis,France.
The mice were backcrossed for more than 10 generations on
a C57BL/6J genetic background. All animals were handled
according to the German guidelines for animal care. All
research involving animals have been conducted according
to guidelines of the German animal protection law.
According to that the local committee for animal welfare at
the University Medicine of Goettingen approved the exper-
iments before the mice were killed.
Immunohistochemistry on parafﬁn sections
Human brain samples from frontal cortex were obtained
from (1) the Netherlands Brain Bank (NBB), Amsterdam,
The Netherlands; (2) the APP Swedish and APP arctic
FAD brain samples from Uppsala University, and the
Presenilin-1 FAD brain samples from the Hopital del la
Salpetrie `re, a generous gift of Prof. Dr. Charles Duyckaerts
and Dr. Veronique Sazdovitch. We did not receive infor-
mation of the cause of death and postmortem delay in all
cases, therefore the information was not added to Table 1.
Tissue was post-ﬁxed in 4% buffered formalin at 4C for
several weeks. Mice were transcardially perfused with 4%
PFA in PBS and brains were carefully dissected. Post-ﬁx-
ation was carried out in 4% buffered formalin at 4C before
the tissue was embedded in parafﬁn. Immunohistochemis-
try was performed on 4 lm sagittal parafﬁn sections, as
described previously (Wirths et al. 2002). In brief, sections
were deparafﬁnized in xylene and rehydrated in a series of
ethanol. After treatment with 0.3% H2O2 in PBS to block
endogenous peroxidases, antigen retrieval was achieved by
boiling sections in 0.01 M citrate buffer pH 6.0, followed
by 3 min incubation in 88% formic acid. Non-speciﬁc
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and fetal calf serum in PBS, prior to the addition of the
primary antibodies. Primary antibodies 4G8 (1 lg/ml),
Ab[N] (2 lg/ml); 2-48 (10 lg/ml) and 1-57 (10 lg/ml),
were incubated overnight in a humid chamber at room
temperature, followed by incubation with biotinylated
secondary antibodies (DAKO, Glostrup, DK) before
staining was visualized using the ABC method with Vec-
tastain kit (Vector Laboratories, Burlingame, USA) and
diaminobenzidine as chromogen providing a reddish brown
color. Counterstaining was carried out with hematoxylin.
Quantiﬁcation of Ab load
For each tissue block, ﬁve parafﬁn-embedded sections, at
least 25 lm apart from each other, were stained simulta-
neously with DAB as chromogen. The relative Ab load
was evaluated using an Olympus BX-51 microscope
equipped with an Olympus DP-50 camera and the ImageJ
software (NIH, USA). Representative pictures of 109
magniﬁcation were systematically captured from the cor-
tex. The pictures were binarized to 8-bit black using
ImageJ and white pictures and a ﬁxed intensity threshold
was applied deﬁning the DAB staining. Measurements
were performed for a percentage of the area covered by
the Ab DAB staining.
Western blot
Peptides including Ab1-42,A b3-42,A bpE11-42 and AbpE3-42
were purchased from Anaspec (San Jose, CA) and recon-
stituted in conditions speciﬁc to each peptide. For each
Western blot, 10 ng of peptide was loaded per lane of a
12% Bis–Tris gel in MES buffer and run at 150 V for 1 h.
The peptides were then transferred to 0.45 lm nitrocellu-
lose for 1 h at 100 mA per membrane using wet transfer in
Towbin buffer. Post-transfer, membranes were incubated in
PBS, pH 9.0 at 95C for 5 min, which allows for improved
access to the antigen. Membranes were then blocked in
2%NFDM/PBS, pH 9.0 for 1 h at room temperature while
gently mixing, before overnight incubation at 4C using the
primary antibody (1-57, 2-48 or HJ5.1) at 1 lg/ml in
blocking buffer, again while gently mixing. Membranes
were rinsed in PBS/0.05%Tween-20 (pH 9.0) three times
for 5 min. Secondary anti-mouse IgG-HRP was applied in
blocking conditions at a 1:10,000 dilution for 1 h at room
temperature. Membranes were rinsed in PBS/0.05%Tween-
20 (pH 9.0) three times for 10 min. The blots were
developed using ECL Advance (GE Healthcare) by
applying the chemiluminescent reagents for 1 min in
reduced light conditions and then imaged on standard ﬁlm
emulsion.
Statistical analysis
Stereological quantiﬁcations were analyzed using two-way
ANOVA followed by t tests. Data are presented as
mean ± SEM. Signiﬁcance levels were given as follows:
***P\0.001, **P\0.01 and *P\0.05. All statistical
analysis was performed using GraphPad Prism version 4.03
for Windows (GraphPad Software, San Diego, CA, USA).
Results
Antibody staining against AbpE3-x
In order to characterize the staining pattern of the two
novel AbpE3 antibodies, formalin-ﬁxed and parafﬁn-
embedded cortical tissue sections from 14 patients with AD
were used (Table 1). Figure 1 shows plaque staining in
Table 1 Demographic data of the human specimen, semi-quantita-
tive plaque load assessment, vessel pathology (congophilic angiopa-
thy, CAA) and Braak staging
Sex Age Plaque load CAA Braak
stage
2-48 4G8 Ab[N]
Control 1 M 74 ?? (?) 4 III
Control 2 F 82 -- -- I
Control 3 F 73 -- -4 I
Control 4 F 79 ?? ?? ? 4 II
Control 5 M 70 ?? ??? ? - 0
Control 6 F 73 ?? ?? (?) - 0
AD 1 M 72 ?? ? (?) - VI
AD 2 M 70 ??? ??? ??? 4 V
AD 3 M 78 ?? ? (?) 4 IV
AD 4 M 60 ??? ??? ? - VI
AD 5 M 93 ?? ?4 IV
AD 6 M 64 ?/?? ?? ? 4 VI
AD 7 F 77 ?? ??? ? - VI
AD 8 F 81 ?? ??? ? - IV
AD 9 F 78 ??? ??? ? - IV
AD 10 F 64 (?) ?? - - III
AD 11 F 88 ??? ??? - 4 IV
AD 12 M 81 ??? ??? ??? 4 IV
AD 13 F 84 ??? ??? - - IV
AD 14 F 84 ??? ??? (?) 4 IV
FAD APP arc M 64 ??? ??? ?/?? 4 n.a.
FAD APP swe F 61 ??? ??? ??? 4 n.a.
FAD PS1 P264L M 54 ??? ??? (?) 4 VI
The three familial AD (FAD) patients harbored an APP Swedish
mutation (APP swe), an APP arctic mutation (APP arc), and a
Presenilin-1 mutation (FAD P264L). Most but not all cases also
showed CAA. Antibodies: 4G8 (Ab 17-24), 2-48 (pGlu Ab) and
Ab[N] (speciﬁc for Ab at position 1)
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There were no signiﬁcant differences between the AbpE3
antibodies 1-57 and 2-48.
Surface plasmon resonance analysis of antibodies
The speciﬁcity and afﬁnity of the antibodies used for
immunohistochemical staining was determined with the
help of surface plasmon resonance analyses (BIAcore).
Equal amounts of the Ab peptides pE3-38, 3-38, and 1-38
were immobilized to a sensor chip surface and various
dilutions of the individual antibody were applied to quan-
tify binding. The resulting sensorgrams clearly demonstrate
an unequivocal speciﬁcity of 1-57 and 2-48 for AbpE3-38
(Fig. 2a, b), while we could hardly detect any binding to
Ab3-38 or 1-38. In contrast to the pGlu-speciﬁc antibodies,
the commercially available antibody Ab[N] exhibited
speciﬁc binding to Ab1-38 when subjected to the respective
sensor surface (Fig. 2c). Hence, this result implies that this
antibody is highly suitable to reveal the presence and
quantity also in brain tissue of full-length Ab species
compared to the shorter species and AbpE3. To further
characterize 1-57 and 2-48, the avidities of both antibodies
were calculated from the steady state of binding activity at
various tested concentrations. The resulting KD-values of
17.7 nM for 1-57 and 9.1 nM for 2-48 conﬁrmed a very
high afﬁnity for both antibodies speciﬁcally recognizing
AbpE3-38.
Western blot showing speciﬁcity of AbpE3-x
antibodies 1-57 and 2-48
In the presence of SDS and under denaturing conditions the
two antibodies against pGlu Ab speciﬁcally detected
AbpE3-42 without any visible cross-reactivity against other
Ab epitopes or pGlu epitope starting with Ab11. The
antibody HJ5.1 recognizes a central epitope of Ab and
therefore stains all peptides loaded (Fig. 2d). Staining
speciﬁcity of transgenic mouse brain lysates using 2-48 has
been shown previously (Wirths et al. 2009).
Dynamic changes of plaque-associated Ab
in the APP/PS1KI transgenic mouse brain
APP/PS1KI mice at 2, 6 and 10 months of age (Fig. 3)
were stained with all four Ab antibodies and plaque load
was quantiﬁed as described earlier (Christensen et al.
2008b). One-way analysis of variance demonstrated sig-
niﬁcant differences between the groups using Ab[N]
(P\0.0005; F = 19.39), 4G8 (P\0.01; F = 14.77),
2-48 (P\0.001; F = 20.67) and 1-57 (P\0.01;
F = 9.196). After Bonferroni correction (statistical sig-
niﬁcances between the groups are presented in Fig. 3) the
mean values were as follows: Ab[N] (mean ± SEM at
2 months 1.7 ± 0.2, 6 months 5.9 ± 0.7 and 10 months
3 ± 0.3); 4G8 (mean ± SEM at 2 months 3.2 ± 0.3,
6 months 9.6 ± 0.6 and 10 months 9.1 ± 1.2); 2-48
Fig. 1 Plaque staining with
pGlu Ab (AbpE3) antibodies in
frontal cortex in sporadic AD
brain. Plaques staining with
antibody 4G8 (a), pGlu Ab
antibodies 2-48 (b) and 1-57(c);
but no staining in plaque-free
healthy control tissue (d, 2-48
staining). Scale bar 100 lm
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123(mean ± SEM at 2 months 0.2 ± 0.1, 6 months 2.0 ± 0.4
and 10 months 4.7 ± 0.8); 1-57 (mean ± SEM at
2 months 0.1 ± 0.1, 6 months 0.8 ± 0.2 and 10 months
2.9 ± 0.9). While there was a peak of Ab1-x at 6 months of
age, total Ab (4G8) reached a plateau at that time point,
and AbpE steadily increased from 2 to 10 months of age.
These data indicate that (1) total Ab plaque burden reaches
a certain level of saturation, (2) Ab starting at position 1 is
degraded and/or truncated at later time points and (3)
N-truncated pGlu Ab is constantly increasing.
Comparison of Ab plaque load in sporadic
and familial AD brain
The plaque staining pattern (Fig. 1), BIAcore and Western
blot analysis (Fig. 2) together with the staining pattern in
the APP/PS1KI mice (Fig. 3) revealed that the speciﬁcity
and afﬁnity of the antibodies 1-57 and 2-48 was very
similar under native and denaturing conditions. Therefore,
only 2-48 was used as an additional antibody for conﬁr-
mation of ﬁndings obtained with the following experi-
ments. Human postmortem brain tissue (frontal cortex from
sporadic AD, FAD and non-demented individuals) was
used to compare staining patterns obtained with this set of
Ab antibodies (Fig. 4). Most of the sporadic and all of the
familial AD (FAD) cases demonstrated high abundance
and similar amount of plaques stained with 4G8 and 2-48.
Plaques stained with Ab[N] were less frequently observed.
We also identiﬁed cases with similar staining using 4G8
and 2-48 (Table 1) indicating that N-terminal truncation
has occurred. While the plaque load per se did not differ
between non-demented controls and AD cases, it is inter-
esting to note that the pattern in human cases resembled the
pattern in APP/PS1KI mice. For example, case AD 5
demonstrated low plaque load according to all three anti-
bodies resembling the pattern seen in 2-month-old mice.
Fig. 2 Binding speciﬁcity of pGlu Ab (AbpE3) antibodies. (a)
Biacore analysis revealed that pGlu antibodies 2-48 (b) and 1-57
speciﬁcally bind to AbpE3-38, not to Ab3-38 and Ab1-38.( c) The
commercial antibody Ab[N] recognizes only Ab1-38, not Ab3-38
or AbpE3-38.( d) 2-48 and 1-57 recognize Ab3p(E)-42, but not Ab1-42,
Ab3-42,o rA b11p(E)-42 under these conditions. Lane 1 Ab1-42, Lane 2
Ab3-42, Lane 3 Ab11p(E)-42, Lane 4 Ab3p(E)-42. 10 ng per well of each
peptide was loaded on 3 separate 12% Bis–Tris gels, transferred to
nitrocellulose and blotted with 1 lg/ml of each primary antibody.
2-48 and 1-57 recognize Ab3p(E)-42,A b1-42,A b3-42,o rA b11p(E)-42
under these conditions
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mice. Interestingly, we never observed high Ab1-x levels in
combination with low AbpE3 reaction as in 6-month-old
mice. All three antibodies stained Ab in blood vessels, a
typical feature of congophilic angiopathy (CAA). We did
not observe any correlation between Braak staging and
plaque pathology. Interestingly, all FAD cases showed
abundant AbpE3 plaques. The FAD cases having an APP
Swedish (APP swe) or APP arctic (APP arc) mutation
demonstrated a similar extent of Ab plaque load. The
Fig. 3 Plaque load analysis in APP/PS1KI mice. Plaque load was
quantiﬁed at 2, 6 and 10 months of age (n = 5, female mice only).
a–c Ab[N] an antibodies speciﬁc for position 1 of Ab showed a peak
at six and a decline at 10 months of age. d–f 4G8 recognizing Ab
17-24 showed an increase between 2 and 6 month of age, while at
10 months the plaque load did not increase any more. Analysis with
the Ab pyroglutamate (AbpE3) antibodies 2-48 (g–i) and 1-57 (j–l)
demonstrated a continuous increase. Scale bar 200 lm
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amount of Ab[N] positive plaques.
Discussion
In the present work, we show that large numbers of plaques
positive for AbpE3 are present in patients with sporadic AD
as has been shown earlier using two novel antibodies. In
addition, we demonstrate that also familial AD including
those carrying mutations in APP (arctic and Swedish) and
PS1 harbor abundant AbpE3plaques. In contrast to a recent
publication (Schilling et al. 2008), we observed that control
cases also harbored AbpE3 positive plaques. The amount of
plaques positive for Ab1-x is less abundant in the control
cases. Interestingly, in APP/PS1KI mice, we observed a
continuous increase in AbpE3 plaque load with increasing
age, while the density for Ab1-x plaques declined with
aging. We therefore assume that, in particular, the peptides
starting with position 1 of Ab are N-truncated as disease
progresses. On the other side, we have demonstrated that
intraneuronal AbpE3-42 expression is highly toxic in vivo,
and that the induced neuron loss is associated with a lethal
neurological phenotype in TBA2 transgenic mice (Wirths
et al. 2009). Saido et al. suggested that the removal of
N-terminal amino acids 1 and 2 of Ab could be carried out
by a hypothetical peptidase (Saido et al. 1995), and very
recently it has been shown that aminopeptidase A may be
responsible for the N-terminal truncation of full-length Ab
peptides (Sevalle et al. 2009). If a subsequent glutamate
cyclization by a glutamate cyclase occurs leading to pGlu
formation, this could protect the peptide from degradation
and even make it more prone to accumulate. The increasing
levels of AbpE3 plaques in APP/PS1KI mice with age could
be due to this effect. To further verify this in vivo, we have
recently generated transgenic mice expressing Ab3E starting
at position 3 with glutamine and ending at position 42
(TBA2 mouse line (Wirths et al. 2009)). The severity of the
Fig. 4 Staining pattern in frontal cortex of sporadic and familial AD
brain. Upper panel showing the staining pattern in a sporadic AD case
using 4G8 (Ab 17-24), 2-48 (pGlu Ab) and Ab[N] (speciﬁc for Ab at
position 1) (a–c). While the staining pattern of 4G8 and 2-48 is
comparable, there is no staining with Ab[N]. Middle panel
comparable levels of plaque load with all three antibodies in a FAD
case with the Swedish mutation. Note abundant vessel staining with
all three antibodies (d–f). Lower panel the same is true for the
staining pattern in a case with the arctic mutation; however, Ab[N]
staining is less abundant (g–i). Scale bar 200 lm
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123neurological phenotype observed in TBA2 mice, accom-
panied by Purkinje cell loss and premature mortality reﬂects
the in vivo toxicity of AbpE3-42. Interestingly, 85% of Ab
peptides in the APP/PS1KI mice terminated at position 42,
whereas the N-terminus shows a large heterogeneity
including AbpE3. The time point of high levels of AbpE3-42
coincided with the onset of behavioral deﬁcits in both
mouse models. We have previously shown that at 6 months,
the APP/PS1KI mice exhibit a neuron loss in CA1 of the
hippocampus (Breyhan et al. 2009; Casas et al. 2004), the
frontal cortex (Christensen et al. 2008b), and in distinct
cholinergic nuclei (Christensen et al. 2008a). Overall, the
pathological events seen in the APP/PS1KI mouse model
might be at least partly triggered by AbpE3-42 accumulation.
N-terminal truncation of Ab seems to be a common
phenomenon in brain material that has been stored for a
long time. In brain material that has been stored only a few
years, much more N-terminally intact Ab is found. The
conclusion from this preliminary study is that the process
of N-terminal truncation might continue while the brain
tissue is kept at -80C (Lars Lannfelt and Martin Ingels-
son, unpublished data). This phenomenon is not likely to
occur in parafﬁn-embedded tissue. However, it cannot be
completely ruled out.
N-truncated AbpE3 peptides have been identiﬁed by
several groups from AD brains (Guntert et al. 2006;
Harigaya et al. 2000; Hosoda et al. 1998; Iwatsubo et al.
1996; Kuo et al. 1997, 2001; Miravalle et al. 2005; Mori
et al. 1992; Piccini et al. 2005, 2007; Russo et al. 1997;
Saido et al. 1995, 1996; Tekirian et al. 1998). N-terminal
deletions, in general, enhance aggregation of b-amyloid
peptides in vitro (Pike et al. 1995). AbpE3 has a higher
aggregation propensity (He and Barrow 1999; Schilling
et al. 2006), and stability (Kuo et al. 1998), and shows an
increased toxicity compared to full-length Ab (Russo et al.
2002). It has been suggested that N-truncated Ab peptides
are formed directly by BACE and not through a progres-
sive proteolysis of full-length Ab1-40/42 (Russo et al. 2001).
In our view this concept is not likely to be the explanation
of the present data, because the increase in pyroglutamate
formation appeared to happen on the expense of full-length
N-terminal Abeta. Our data are in good agreement with a
previously published paper by Guntert et al. (2006). It was
found that in cored plaques there was an increase of N-
terminal truncations of approximately 20% between Braak
stages IV–VI. In contrast, diffuse plaques of AD and
control cases showed consistently only low levels of
amino-terminal truncations. Whether or not AbpE3 is acting
as a seed for plaque formation is a matter of current sci-
entiﬁc debate. Up to now there is no sufﬁcient proof (or
disproof) that this is actually the case. AbpE3 formation (in
plaques) appears to be a late process involved in the mat-
uration of plaques rather than in the seeding of plaques. On
the other side, it is obvious that intraneuronal AbpE3-42
accumulation initiates an early lethal phenotype in TBA2
mice associated with massive neuron loss, atrophy and
neurological behavioral deﬁcits (Wirths et al. 2009). In in
vitro experiments Schilling et al. have shown that cycli-
zation of glutamate at position 3 of Ab can be driven
enzymatically by glutaminyl cyclase (QC) (Schilling et al.
2004). In addition, it has been demonstrated that QC
inhibition signiﬁcantly reduced AbpE3 formation, empha-
sizing the importance of QC activity during cellular mat-
uration of pyroglutamate-containing peptides. The
pharmacological inhibition of QC activity by the QC
inhibitor P150, which signiﬁcantly reduced the level of
AbpE3 in vitro (Cynis et al. 2006) and in vivo (Schilling
et al. 2008), suggests that QC inhibition might serve as a
new therapeutic approach. In addition, we have investi-
gated the level of IgM autoantibodies directed against
different Ab epitopes as potential diagnostic biomarker for
AD (Marcello et al. 2009). Anti-Ab autoantibody levels
were measured in 75 plasma samples from patients with
AD, individuals with mild cognitive impairment (MCI),
and healthy age- and sex-matched controls. The mean level
of AbpE3-IgM was signiﬁcantly decreased in AD patients
as compared to healthy controls. In the group of MCI
patients there was a signiﬁcant positive correlation between
AbpE3-IgM and cognitive decline analyzed by MMSE
(rho = 0.58, df = 13, P = 0.022). These observations
indicate that the level of IgM autoantibodies against AbpE3
is a promising plasma biomarker for AD and correlates
with the cognitive status of individuals at risk to develop
AD. It is, however, tempting to speculate that the corre-
lation of the cognitive status in MCI patients with lower
levels of AbpE3-IgM in plasma might be due to early
changes in AbpE3-induced neurodegeneration prior to
clinical diagnosis of AD. Overall, the importance of AbpE3
in AD pathology is an issue of increasing interest. We
believe that the present manuscript adds further evidence
that N-terminal pE-modiﬁed Ab in plaques is continuously
increasing on the expense of Ab1-x. The consequences of
continuous rearrangement of plaque Ab by pyroglutamate
formation are presently unclear.
Animal models aim to replicate the symptoms, the
lesions or the cause(s) of Alzheimer disease. Mutated
human APP expression results in the deposition of Ab
peptide, similar but not identical to the Ab peptide of
human senile plaque (reviewed in Duyckaerts et al. 2008).
APP transgenic mouse models have been reported to show
no (Kuo et al. 2001) or low AbpE3 levels (Guntert et al.
2006). Maeda et al. have demonstrated that the localization
and abundance of [11C]PIB autoradiographic signals were
closely associated with those of amino-terminally truncated
and modiﬁed Ab3pE deposition in AD and different APP
transgenic mouse brains, implying that the detectability of
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123amyloid by [11C]PIB-PET is dependent on the accumula-
tion of speciﬁc Ab subtypes (Maeda et al. 2007). An
emerging role of intracellular Ab accumulation has been
previously shown in human AD (D’Andrea et al. 2002;
Gouras et al. 2000) while it has been observed that Ab
localizes predominantly to abnormal endosomes (Cataldo
et al. 2004), multivesicular bodies and within pre- and
postsynaptic compartments (Langui et al. 2004; Takahashi
et al. 2002). Takahashi et al. demonstrated that Ab42
aggregates into oligomers within endosomal vesicles and
along microtubules of neuronal processes, both in cultured
neurons of Tg2576 mice, as well as in Tg2576 and human
AD brain (Takahashi et al. 2004). In in vitro experiments,
Schilling et al. have shown that cyclization of glutamate at
position 3 of Ab can be driven enzymatically by glutaminyl
cyclase (QC) (Schilling et al. 2004). In addition, it has been
shown that QC inhibition signiﬁcantly reduced AbpE3 for-
mation, emphasizing the importance of QC activity during
cellular maturation of pyroglutamate-containing peptides
(Cynis et al. 2006). The pharmacological inhibition of QC
activity by the QC inhibitor P150, which signiﬁcantly
reduced the level of AbpE3 in vitro (Cynis et al. 2006) and
in vivo (Schilling et al. 2008) suggests that QC inhibition
might serve as a new therapeutic approach to rescue AbpE3
triggered neurodegeneration in AD.
In summary, we have shown that AbpE3 plaques are
abundant in sporadic and familial AD cases, and that at
least in the APP/PS1KI mouse model, the AbpE3 plaque
load increases in an age-dependent manner, which is not
the case for total Ab and Ab1-x. Most recently, it has been
shown that plaque load in non-demented individuals con-
stantly increases with aging, while it decreases in AD
patients older than 95 years (Savva et al. 2009). At present
there is a lack of information on AbpE3 plaque load in such
a cohort of individuals. It would be interesting to study the
heterogeneity of N-terminal variant Ab peptides, since we
observed that only Ab1-x plaques declined with aging in the
APP/PS1KI mice and were less frequent in sporadic and
familial AD cases. It is tempting to speculate that the
continuous increase in AbpE3 between 6 and 10 months in
APP/PS1KI mice is due to a corresponding truncation of
full-length Ab-peptides, as the overall plaque load, as
shown by 4G8 staining, is stable in that time period. Future
studies will provide a better understanding of the conse-
quence of N-truncated Ab for AD progression.
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